The relationship of cardiovascular complications and disorders of bone mineral metabolism in patients on hemodialysis

THE AIM. Clarify the possible pathogenic relationship between markers of bone and mineral metabolism and markers of cardiovascular diseases, characterizing the state of the myocardium and aorta vessel wall in patients on renal replacement therapy. PATIENTS AND METHODS: We examined 95 patients with chronic kidney disease (CKD) VD stage: 45 men and 50 women aged from 25 to 68 years (mean age 54 ± 2,4). Levels of calcium, phosphorus, parathyroid hormone (PTH), morphogenetic protein FGF-23, cardiospecific proteins - troponin were estimated I. We studied the morphological and functional characteristics of the left ventricle (LV) and the aorta. Determined the LV myocardium mass index (LVMMI), blood flow peak systolic velocity in the aortic arch (Vps). Echocardiography with Doppler was performed on “ALOKA 4000”. RESULTS. Changes in bone and mineral metabolism, including an increase of the FGF- 23 level in patients with end-stage renal failure, were closely related to the increase in LVMMI, decrease of ejection fraction (EF) of the left ventricle and increased troponin I levels. CONCLUSION. In patients with end-stage renal failure revealed changes in bone and mineral metabolism, including increased FGF-23 levels from moderate to very high numbers, which indicates a high risk of remodeling processes in the cardiovascular system (CVS ), even when the initial absence EHO CT signs of myocardial hypertrophy and aortic lesions. It is necessary to take it into account when determing cardioprotective therapy tactics.

23-й фактор роста фибробластов, end-stage renal failure, bone mineral metabolism disturbances, cardiovascular complications, fibroblast growth factor-23 , troponin I

1. Мухин НА. Хроническая болезнь почек. Клиническая фармакология и терапия 2011;4:70-75

2. Смирнов AB, Волков ММ, Добронравов ВА, Рафрафи Х. Фосфорно-кальциевый обмен и состояние сердечно-сосудистой системы у пациентов с ранними стадиями хронической болезни почек. Тер арх 2010;( 6):45-49

3. Kendrick J, Cheung AK, Kaufman JS et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011;22:1913-1922. doi: 10.1681/ ASN.2010121224.

4. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010,'21: 1427-1435. doi: 10.1681/ASN.2009121293.

5. Добронравов ВА, Васильева ИА, Бабарыкина ЕВ. Качество жизни и отдаленная сердечно-сосудистая выживаемость больных на гемодиализе. Нефрология 2016;20(3):84-95

6. Isakova TIxJ, Sprague SM, Raphae K et al. Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. Journal of the American Society of Nephrology 2015;26(10):2328-2339 doi:10.1681/ASN.2015020117

7. Foley RN, Parfrey PS, Harnett JD. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-192. doi: 10.1038/ki.1995.22

8. Hassan A, Durlacher K, Silver J et al. The fibroblast growth factor receptor mediates the increased FGF23 expression in acute and chronic uremia Am J Physiol Renal Physiol 2016 ;310(3):F217-

9. Руденко ЛИ, Батюшин ММ, Кастанаян АА, Воробьев БИ.Прогнозирование риска развития кардиоваскулярной кальцификации у пациентов, получающих хронический гемодиализ. Нефрология 2015;5:76-80

10. Дзгоева ФУ, Сопоев МЮ, Бестаева ТЛ и др. Фактор роста фибробластов-23 и сердечно-сосудистые осложнения при хронической болезни почек. Нефрология 2015; 19(5):56-62

11. Mathew JS,Sachs MC, Katz R et al. Fibroblast growth factor-23 and incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation 2014;130:298-307. doi:10.1161/CIRCULA-TI0NAHA.113.005499.

12. Felsenfeld AJ, Levine BS, Rodriguez M. Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease. Semin Dial 2015;28(6):564-577. doi: 10.1111/sdi.12411

13. Mace ML, Gravesen E, Hofman-Bang J et al. Key role of the kidney in the regulation of fibroblast growth factor 23. Kidney Int 2015; 88: 1304-1313. doi: 10.1038/ki.2015.231

14. Jimbo R, Kawakami-Mori F, Mu S et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int 2014,85:11031111. doi:10.1038/ki.2013.332

15. Cozzolino M, Cosa F, Ciceri F et al. Vascular calcification in chronic kidney disease. EMJNeph 2013;1:46-51. doi: 10.1016/j. advms.2015.09.004.

16. Kurnatowska I, Grzelak P, Kaczmarska M et al. Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. Nephron Clin Pract 2011; 117:297-304. doi: 10.1159/000321169.

17. Рафрафи Х, Румянцев АШ. Статус витамина D и состояние сердечно-сосудистой системы у пациентов с хронической болезнью почек С5Д стадии. Нефрология 2015; 19(4):54-58

18. Дзгоева ФУ, Сопоев МЮ, Гатагонова ТМидр. 23-й фактор роста фибробластов (FGF-23) и новый высокочувствительный тропонин I: ранние маркеры и альтернативные пути поражения сердца при хронической болезни почек. Тер арх 2015; 6:69-74

19. Hsu JJ, Katz R, Ix J et al. Association of fibroblast growth factor-23 with arterial stiffness in the Multiethnic Study of Atherosclerosis (MESA). Nephrol Dial Transplant 2014;29:2099-2105. doi: 10.1093/ndt/gfu101

20. Smith ER, Ford ML, Tomlinson LA et al. Serum Calcification Propensity Predicts All-Cause Mortality in Predialysis CKD.JASN 2014; 25: 339-348. doi: 10.1681/ASN.2013060635

21. Isakova Т. An Introduction to PTH, Phosphate and Vitamin D: Current Issues and Concerns Seminars in Dialysis. 2015;28(6):563. doi:10.1111/sdi.12445

22. Scialla JJ, Rahman M. Fibroblast Growth Factor-23 and Cardiovascular Events in CKD. J Am Soc Nephrol 2014; 25: 349360. doi: 10.1681/ASN.2013050465

23. Faul C, Amaral AP, Oskouei B. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408. doi: 10.1172/JCI46122